Deanna Pogorelc from wrote an interesting article on the impact middle market pharma companies are having on mergers and acquisitions in the pharmaceutical industry. PwC reported in their yearend report on the industry that 2013 was up 46% in transactions versus 2012. In the same report PwC stated that a major difference shown in 2013 than was the lack of mega deals. Pogorelc goes on to explain that middle market companies are being picked up for their products to help major players increase their portfolio value. An example of this occurring is the acquisition of Bard EP by to help their electrophysiology sector. Read more here about how these mid-market companies are helping the pharma giants diversify their companies.